Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02045732 · ClinicalTrials.gov registry record · Phase 1
A Study To Evaluate The Safety And Tolerability Of PF-06342674 (RN168) In Subjects With Multiple Sclerosis (MS)
A Phase 1 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 1
- Development phase
- 4
- Enrollment target
NCT02045732: Clinical Trial Phase 1 study, sponsored by Pfizer.
NCT02045732 is a Phase 1 study that was terminated before completion, run by Pfizer. The registered enrollment target is 4 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02045732, a Phase 1 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 4 participants
- Enrollment target
Study Summary
PF-06342674 (RN168), being developed for the treatment of multiple sclerosis (MS), is an antibody that binds to and inhibits the human interleukin-7 receptor, a component potentially involved in MS. PF-06342674 (RN168) is expected to play a role in slowing down the progression of the disease.
Primary Outcome
An AE was any untoward medical occurrence in a participant who received study drug. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent AEs are events between first dose of study drug and up to Day 127/Early Termination that were absent before treatm
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL PF-06342674 0.25 mg/kg
- BIOLOGICAL PF-06342674 1.5 mg/kg
- BIOLOGICAL PF-06342674 6.0 mg/kg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2014-09 |
| Est. Completion | 2015-10 |
| Phase | Phase 1 |
Why NCT02045732 stopped before completion
NCT02045732 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 4 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (93% lower).
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT02045732 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02045732 about?
NCT02045732 is a clinical study titled "A Study To Evaluate The Safety And Tolerability Of PF-06342674 (RN168) In Subjects With Multiple Sclerosis (MS)". PF-06342674 (RN168), being developed for the treatment of multiple sclerosis (MS), is an antibody that binds to and inhibits the human interleukin-7 receptor, a component potentially involved in MS. PF-06342674 (RN168) is expected to play a role in slowing down the progression of the disease.
What is the current status of trial NCT02045732?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2014-09. Estimated completion is 2015-10.
What interventions are being tested in trial NCT02045732?
The interventions under investigation include: Placebo (BIOLOGICAL), PF-06342674 0.25 mg/kg (BIOLOGICAL), PF-06342674 1.5 mg/kg (BIOLOGICAL), PF-06342674 6.0 mg/kg (BIOLOGICAL).
Who is sponsoring clinical trial NCT02045732?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02045732's enrollment target sits among peer trials
4 1995th of 2000 higher than 2 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia